Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 94Carcinoma, Non-Small-Cell Lung 84Prostatic Neoplasms 74Multiple Myeloma 74Neoplasms 46Melanoma 41Lymphoma 41Leukemia, Myeloid, Acute 41Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 34Lung Neoplasms 34Lymphoma, Non-Hodgkin 33Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 28Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 20Lymphoma, Follicular 20Fallopian Tube Neoplasms 20Carcinoma, Renal Cell 20Sarcoma 19Urinary Bladder Neoplasms 18Recurrence 18Head and Neck Neoplasms 18Small Cell Lung Carcinoma 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17

Interventions

Sunitinib 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Neoplasms × 90 days × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡